Return-Path: Delivered-To: andrew@sterlingcal.com Received: from reseller401.webserversystems.com by reseller401.webserversystems.com with LMTP id +GZhAyIH/WdyoQsAchKAPA (envelope-from ) for ; Mon, 14 Apr 2025 08:01:22 -0500 Return-path: Envelope-to: andrew@sterlingcal.com Delivery-date: Mon, 14 Apr 2025 08:01:22 -0500 Received: from r68.info.wiley.com ([172.82.209.68]:42714) by reseller401.webserversystems.com with esmtps (TLS1.2) tls TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384 (Exim 4.98.1) (envelope-from ) id 1u4JRB-00000003Crk-2MIG for andrew@sterlingcal.com; Mon, 14 Apr 2025 08:01:21 -0500 DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=info.wiley.com; s=wileypublishing; t=1744635667; bh=Ub/q1GQGhwcULEPDyAcuw11QBw3n7DqXuOhtXjoEdpU=; h=From:Subject:Date:To:MIME-Version:Message-ID:List-Unsubscribe: Content-Type; b=pJry3U266pMKMZFQFrS0UMLwbZ9xUvxzyoMlgi35tBhsenN89msFTN4EVDEsxbx7u NKcJElnvzsZlkrEQHV7WvbPkQYHPma/WrzN7EbeYi1LbV0IEAMAMJ7IcL2Wmm9/zoo ddU9JWe0Rv6IFF3qvrAws4quyob1bVwb1camyY/Ktv928UIfYzvofvFnPCwrhNuu0R yhFrzYvkHD1EUclC9nm9PbRkzb5C+ZktzR/5GVQaEVELWiFlUMYgIgcCHFvOh/wdDp 20/z8A0t0HwsujGZgolEiVg5EI/ZwSrUZ+MkL2mEb/Zpm8tZ8Y/OWVLleeDS3Q+98T EHiZ6FYqbzj0g== X-MSFBL: 88ynpT7iY6EqFGdkdN/+ZYVZG0y+2Rkbq+rUwu2pMwU=|eyJyY3B0X21ldGEiOns gImluIjogIndpbGV5cHVibGlzaGluZ19taWRfcHJvZDciLCAiciI6ICJhbmRyZXd Ac3RlcmxpbmdjYWwuY29tIiwgIm0iOiAiMWUxZDc1NTktMDgxYS00ZjE5LTk0NTc tNTI4NmE0ZTI3MDQxIiwgImQiOiAiNzcwNzAxOSIsICJpIjogIjFCNkUzNEI4NTI 4MkEwQUMwQTQ5MEQ0NEBBZG9iZU9yZyIgfSwiYiI6IndpbGV5cHVibGlzaGluZ18 xNzIuODIuMjA5LjY4X3Byb2Quam9obndpbGV5bWFya2V0aW5nXzlmYmFmN2YwLTU 2N2QtNDVhOS1hYjJlLTQwOGM5YzU2YTY3NSIsImciOiJwcm9kLmpvaG53aWxleW1 hcmtldGluZ185ZmJhZjdmMC01NjdkLTQ1YTktYWIyZS00MDhjOWM1NmE2NzUiLCJ yIjoiYW5kcmV3QHN0ZXJsaW5nY2FsLmNvbSJ9 Received: from [10.1.1.129] ([10.1.1.129:35639] helo=r67.info.wiley.com) by or2-prod1-mta-i-0f3ad282d86e702f0 (envelope-from ) (ecelerity 4.4.1.20033 r(msys-ecelerity:tags/4.4.1.0^0)) with ESMTP id F8/D9-07680-2170DF76; Mon, 14 Apr 2025 13:01:07 +0000 From: "Wiley" Subject: Learn from experts: Managing sequence variants in protein therapeutics Date: Mon, 14 Apr 2025 09:01:06 -0400 To: Reply-To: "Wiley" MIME-Version: 1.0 X-mailer: nlserver, Build 8.6.4 Message-ID: List-Unsubscribe: Content-Type: text/html; charset="windows-1252" Content-Transfer-Encoding: quoted-printable X-Spam-Status: No, score=-4.0 X-Spam-Score: -39 X-Spam-Bar: ---- X-Spam-Flag: NO

If you are unable to view this message correctly, click here

You=92re invited

Dive into the= world of biotherapeutics with our upcoming webinar! We'll explore the impa= ct of sequence variants on protein therapeutics and reveal cutting-edge det= ection methods. Learn from real-world case studies and gain valuable insigh= ts that will enhance your understanding and expertise.

What to expect:

•	<= span style=3D"font-size: 14px;">Understand the impact of sequence variants = on drug efficacy, stability, and immune responses.
•	<= span style=3D"font-size: 14px;">Discover detection methods using icIEF-UV/M= S and EAD-enabled LC/MS techniques.
•	<= span style=3D"font-size: 14px;">Explore a real-world case study on identify= ing and mitigating a sequence variant.

Ready to get = started=3F Register now to secure your spot!

REGISTER NOW

Speaker information

Kristen Nields, Principal Scientist
Johnson & Johnson Innovative Medicine

Kristen Nields is the Principal Scientist in the Cell and Developab= ility Group at Johnson & Johnson Innovative Medicine with 20+ years of expe= rience in the biopharma industry. She specializes in bridging mass spectrom= etry and product quality functions to enhance communication. Kristen is rec= ognized for developing innovative analytical methods within the Johnson & J= ohnson organization to close product knowledge gaps.

Riley Schaefer, Co-Op Scientist II
Johnson & Johnson Innovative Medicine

Riley Schaefer is a recent honors graduate from St. Joseph=92s Univ= ersity with a B.S. in Biochemistry. He currently works as the Analytical Ce= ll Engineering & Development Co-Op at Johnson & Johnson Innovative Medicine= . His focus is on developing analytical methods to assess the biophysical p= roduct quality of monoclonal and multi-specific antibodies for the purpose = of engineering an array of manufacturing cell lines.

This virtua= l seminar has been made possible through sponsorship from Sciex.

= ; &nb= sp; =

=A9 John Wiley & Sons, Inc. All rights reserve= d.